Kenvue Sees Unusually High Options Volume (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) was the recipient of unusually large options trading on Tuesday. Traders bought 106,657 call options on the stock. This is an increase of approximately 851% compared to the typical daily volume of 11,211 call options.

Kenvue Stock Performance

KVUE stock traded down $0.13 during trading on Tuesday, hitting $23.65. 10,708,438 shares of the company traded hands, compared to its average volume of 18,088,291. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. Kenvue has a 1 year low of $17.67 and a 1 year high of $23.95. The stock’s 50-day simple moving average is $22.68 and its 200 day simple moving average is $20.58. The company has a market cap of $45.29 billion, a PE ratio of 43.00, a P/E/G ratio of 3.10 and a beta of 1.36.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.41% and a net margin of 6.88%. Kenvue’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.31 EPS. On average, equities analysts expect that Kenvue will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.47%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Institutional Investors Weigh In On Kenvue

Large investors have recently modified their holdings of the business. Leo Wealth LLC grew its position in Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares during the period. Massmutual Trust Co. FSB ADV raised its position in Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC lifted its stake in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares during the last quarter. Marathon Capital Management increased its holdings in Kenvue by 0.3% in the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after buying an additional 514 shares during the last quarter. Finally, Poehling Capital Management INC. raised its position in shares of Kenvue by 0.5% during the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock worth $1,908,000 after acquiring an additional 547 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Piper Sandler lifted their target price on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, UBS Group increased their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.